ZNF25 as an immunotherapy target: pan-cancer biomarker potential and mechanistic exploration in glioma - Takeaways - MDSpire

ZNF25 as an immunotherapy target: pan-cancer biomarker potential and mechanistic exploration in glioma

  • By

  • Xiaohong Yi

  • Xianwen Zhang

  • Lijun Huang

  • Yuhui Chen

  • Maochun You

  • Hongyi Jia

  • Lefeng Hou

  • Chao Hu

  • Kun Huang

  • Yumei Wang

  • June 2, 2026

  • 0 min

Share

  • 1

    ZNF25 is identified as a potential biomarker in ovarian cancer, with its significance in other malignancies remaining largely unclear.

  • 2

    A systematic pan-cancer analysis revealed ZNF25's associations with poor prognosis and immune infiltration across multiple cancer types.

  • 3

    Functional assays demonstrated that ZNF25 knockdown inhibited glioma cell proliferation and migration.

  • 4

    Transcriptomic analysis indicated that ZNF25 promotes glioma progression through positive modulation of the PI3K-AKT pathway.

  • 5

    The study highlights ZNF25's potential as a diagnostic and prognostic biomarker, particularly relevant to glioma.

Original Source(s)

ZNF25 as an immunotherapy target: pan-cancer biomarker potential and mechanistic exploration in glioma

  • by Xiaohong Yi, Xianwen Zhang, Lijun Huang, Yuhui Chen, Maochun You, Hongyi Jia, Lefeng Hou, Chao Hu, Kun Huang, Yumei Wang

  • June 2, 2026

Related Content

Diagnosis and treatment of neurofibromatosis type 1 with malignant transformation and multiple gastrointestinal stromal tumors: a case report and literature review

Case Report: Response to ivosidenib in patients with cholangiocarcinoma: a clinical perspective with illustrative cases

Case series analysis of immunophenotypic evolution during recurrence of low-grade endometrial stromal sarcoma: implications for molecular stability and clinical management